Basic Information
Ixchiq
Regulatory Information
EMEA/H/C/005797
Authorised
June 28, 2024
May 30, 2024
2
July 18, 2024
Company Information
Austria
Campus Vienna Biocenter 3 Landstrasse A-1030 Vienna
Valneva Austria GmbH
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication IXCHIQ is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years and older. The use of this vaccine should be in accordance with official recommendations.
Overview Summary
Ixchiq is a vaccine used to help protect adults against disease caused by the chikungunya virus. Ixchiq contains a strain of chikungunya virus that has been attenuated (weakened).